163 related articles for article (PubMed ID: 37762316)
1. An EGCG Derivative in Combination with Nimotuzumab for the Treatment of Wild-Type EGFR NSCLC.
Huang Y; Cuan X; Zhu W; Yang X; Zhao Y; Sheng J; Zi C; Wang X
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762316
[TBL] [Abstract][Full Text] [Related]
2. Oxidized tea polyphenol (OTP-3) targets EGFR synergistic nimotuzumab at inhibition of non-small cell lung tumor growth.
Huang Y; Cuan X; Yang X; Zhu W; Zhao Y; Jiang L; Zi C; Wang X; Sheng J
Bioorg Chem; 2022 Nov; 128():106084. PubMed ID: 35970070
[TBL] [Abstract][Full Text] [Related]
3. (-)-Epigallocatechin-3-gallate derivatives combined with cisplatin exhibit synergistic inhibitory effects on non-small-cell lung cancer cells.
Wang J; Sun P; Wang Q; Zhang P; Wang Y; Zi C; Wang X; Sheng J
Cancer Cell Int; 2019; 19():266. PubMed ID: 31636509
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth.
Yao N; Wang CR; Liu MQ; Li YJ; Chen WM; Li ZQ; Qi Q; Lu JJ; Fan CL; Chen MF; Qi M; Li XB; Hong J; Zhang DM; Ye WC
Signal Transduct Target Ther; 2020 Oct; 5(1):214. PubMed ID: 33033232
[TBL] [Abstract][Full Text] [Related]
5. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
[TBL] [Abstract][Full Text] [Related]
6. A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01).
Kim HR; Jang JS; Sun JM; Ahn MJ; Kim DW; Jung I; Lee KH; Kim JH; Lee DH; Kim SW; Cho BC
Oncotarget; 2017 Feb; 8(9):15943-15951. PubMed ID: 27823977
[TBL] [Abstract][Full Text] [Related]
7. Nimotuzumab and cetuximab block ligand-independent EGF receptor signaling efficiently at different concentrations.
Berger C; Krengel U; Stang E; Moreno E; Madshus IH
J Immunother; 2011 Sep; 34(7):550-5. PubMed ID: 21760527
[TBL] [Abstract][Full Text] [Related]
8. Effect of Epigallocatechin-3-Gallate on EGFR Signaling and Migration in Non-Small Cell Lung Cancer.
Minnelli C; Cianfruglia L; Laudadio E; Mobbili G; Galeazzi R; Armeni T
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769263
[TBL] [Abstract][Full Text] [Related]
9. Nimotuzumab enhances radiation sensitivity of NSCLC H292 cells in vitro by blocking epidermal growth factor receptor nuclear translocation and inhibiting radiation-induced DNA damage repair.
Teng K; Zhang Y; Hu X; Ding Y; Gong R; Liu L
Onco Targets Ther; 2015; 8():809-18. PubMed ID: 25926742
[TBL] [Abstract][Full Text] [Related]
10. A phase I study of nimotuzumab plus docetaxel in chemotherapy-refractory/resistant patients with advanced non-small-cell lung cancer.
Zhao J; Zhuo M; Wang Z; Duan J; Wang Y; Wang S; An T; Wu M; Wang J
Chin J Cancer Res; 2016 Feb; 28(1):12-8. PubMed ID: 27041923
[TBL] [Abstract][Full Text] [Related]
11. Conformational Insight on WT- and Mutated-EGFR Receptor Activation and Inhibition by Epigallocatechin-3-Gallate: Over a Rational Basis for the Design of Selective Non-Small-Cell Lung Anticancer Agents.
Minnelli C; Laudadio E; Mobbili G; Galeazzi R
Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32138321
[TBL] [Abstract][Full Text] [Related]
12. Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivo.
Nitta Y; Shimizu S; Shishido-Hara Y; Suzuki K; Shiokawa Y; Nagane M
Cancer Med; 2016 Mar; 5(3):486-99. PubMed ID: 26778701
[TBL] [Abstract][Full Text] [Related]
13. Nimotuzumab enhances the sensitivity of non-small cell lung cancer cells to tumor necrosis factor-α by inhibiting the nuclear factor-кB signaling pathway.
Zhu J; Xin Y; Liu X; Wang Y; Liu Y
Exp Ther Med; 2018 Apr; 15(4):3345-3351. PubMed ID: 29545853
[TBL] [Abstract][Full Text] [Related]
14. Nimotuzumab increases the anti-tumor effect of photodynamic therapy in an oral tumor model.
Bhuvaneswari R; Ng QF; Thong PS; Soo KC
Oncotarget; 2015 May; 6(15):13487-505. PubMed ID: 25918252
[TBL] [Abstract][Full Text] [Related]
15. Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death.
Chen P; Huang HP; Wang Y; Jin J; Long WG; Chen K; Zhao XH; Chen CG; Li J
J Exp Clin Cancer Res; 2019 Jun; 38(1):254. PubMed ID: 31196210
[TBL] [Abstract][Full Text] [Related]
16. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.
Chong DQ; Toh XY; Ho IA; Sia KC; Newman JP; Yulyana Y; Ng WH; Lai SH; Ho MM; Dinesh N; Tham CK; Lam PY
BMC Cancer; 2015 Apr; 15():255. PubMed ID: 25886314
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations.
Mukohara T; Engelman JA; Hanna NH; Yeap BY; Kobayashi S; Lindeman N; Halmos B; Pearlberg J; Tsuchihashi Z; Cantley LC; Tenen DG; Johnson BE; Jänne PA
J Natl Cancer Inst; 2005 Aug; 97(16):1185-94. PubMed ID: 16106023
[TBL] [Abstract][Full Text] [Related]
18. QSAR modeling, pharmacophore-based virtual screening, and ensemble docking insights into predicting potential epigallocatechin gallate (EGCG) analogs against epidermal growth factor receptor.
Bommu UD; Konidala KK; Pabbaraju N; Yeguvapalli S
J Recept Signal Transduct Res; 2019 Feb; 39(1):18-27. PubMed ID: 31223050
[TBL] [Abstract][Full Text] [Related]
19. Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
Howe GA; Xiao B; Zhao H; Al-Zahrani KN; Hasim MS; Villeneuve J; Sekhon HS; Goss GD; Sabourin LA; Dimitroulakos J; Addison CL
PLoS One; 2016; 11(3):e0150567. PubMed ID: 26962872
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
